Former chief of the Breast Medicine Service at Memorial Sloan Kettering and ASCO president in 2013-2014. Has served as ASCO's CEO since 2016, overseeing its meetings, journals, guidelines, and CancerLinQ.
| Title | Journal | Year |
|---|---|---|
| Trastuzumab--mechanism of action and use in clinical practice | New England Journal of Medicine | 2007 |
| Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system | Journal of Clinical Oncology | 2007 |
Pages like this
not linked directly; found by shared links- PersonJame Abraham
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- PersonShinji Ohno
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- PersonJonas Bergh
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- ProductPegulicianine
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- PersonLori J. Pierce
Shares American Society of Clinical Oncology (ASCO), HR-positive / HER2-negative breast cancer.
- IdeaPublic country dashboards for the three WHO breast cancer targets
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- PersonThomas Bachelot
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- IdeaOne-stop breast clinics: imaging, biopsy and a preliminary answer in a single visit
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.